0QN1.LSE Santhera Pharmaceuticals Holding AG
- Market cap
- GBP 201M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0QN1.LSE undervalued?
Graham numberThe Graham number of Santhera Pharmaceuticals Holding AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Santhera Pharmaceuticals Holding AG fundamental analysis
No fundamental analysis for Santhera Pharmaceuticals Holding AG yet.
Santhera Pharmaceuticals Holding AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Full company profileSanthera Pharmaceuticals Holding AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Santhera Pharmaceuticals Holding AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.0M | 22.9M | 31.7M | 75.4M | 15.0M | -1.60M | 7.47M | 103M | 39.1M | 77.2M | 193M |
| Gross Profit | 14.9M | 18.5M | 26.3M | 68.2M | 479K | -6.05M | 3.27M | 99.5M | 23.0M | 14.5M | 71.8M |
| Operating Income | -33.4M | -50.7M | -51.5M | -6.60M | -53.6M | -57.1M | -45.9M | 68.8M | -33.4M | -37.8M | -26.8M |
| EBITDA | -29.9M | -44.1M | -45.6M | -7.54M | -53.4M | -34.6M | -46.8M | 79.2M | -15.9M | -32.1M | -15.4M |
| Net Income | -35.4M | -51.5M | -54.2M | -19.0M | -67.7M | -55.5M | -71.1M | 54.8M | -42.0M | -49.2M | -86.1M |
| EPS | -56 | -82 | -79 | -17 | -51 | -16 | -12 | 4.91 | -3.69 | -3.78 | -6.00 |
| Balance Sheet | |||||||||||
| Total Assets | 90.8M | 110M | 110M | 115M | 88.7M | 91.1M | 63.7M | 110M | 152M | 148M | 147M |
| Total Liabilities | 16.4M | 77.5M | 82.5M | 93.8M | 95.0M | 89.8M | 107M | 49.7M | 125M | 160M | 153M |
| Shareholders' Equity | 74.4M | 32.3M | 27.8M | 21.2M | -6.35M | 1.33M | -43.7M | 59.9M | 27.7M | -11.8M | -6.17M |
| Cash & Short-term Investments | 49.8M | 61.2M | 25.0M | 32.9M | 12.4M | 21.2M | 1.35M | 30.4M | 40.9M | 22.4M | 41.8M |
| Total Debt | - | 53.1M | 54.6M | 60.0M | 71.2M | 49.3M | 52.5M | 21.5M | 40.6M | 97.8M | 41.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.1M | -39.6M | -37.9M | 2.60M | -43.5M | -37.4M | -29.8M | 47.3M | -35.5M | -34.8M | 59.3M |
| Capital Expenditure | 375K | 1.40M | 21.6M | 229K | 34.0K | 15.0K | 3.96M | 90.0K | 151K | 52.0K | 152K |
| Free Cash Flow | -27.5M | -41.0M | -59.5M | 2.37M | -43.5M | -37.4M | -33.8M | 47.2M | -35.7M | -34.8M | 59.1M |
| Ratios | |||||||||||
| ROE | -47.6% | -159.8% | -194.7% | -89.3% | - | -4,181.2% | - | 91.4% | -151.5% | - | - |
| ROA | -39.0% | -46.9% | -49.1% | -16.5% | -76.3% | -60.9% | -111.5% | 50.0% | -27.5% | -33.2% | -58.5% |
| Net Profit Margin | -186.1% | -224.6% | -171.2% | -25.2% | -450.8% | - | -951.1% | 53.0% | -107.3% | -63.8% | -44.5% |
| Debt to Equity | - | 1.65x | 1.96x | 2.82x | - | 37.16x | - | 0.36x | 1.47x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Santhera Pharmaceuticals Holding AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | GBP 739K | 0.22 | - |
| 2020 | GBP 1.07M | 0.80 | - |
| 2019 | GBP 4.13M | 3.76 | - |
| 2018 | - | - | - |
| 2017 | CHF 57.1M | 91 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 0.1:1 on Jul 3, 2023.
Who owns Santhera Pharmaceuticals Holding AG
- Insiders 11.15%
- Institutions 16.76%
- Public & others 72.08%
- Shares outstanding 6.44M
- Free float 12.6M
Santhera Pharmaceuticals Holding AG company profile
- Company name
- Santhera Pharmaceuticals Holding AG
- Ticker
- 0QN1.LSE
- ISIN
- CH1276028821
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 93
- Fiscal year end
- December
- Address
- Hohenrainstrasse 24, Pratteln, Switzerland, 4133
- Phone
- 41 61 906 89 50
- Website
- santhera.com
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Santhera Pharmaceuticals Holding AG management
10- Dr. Thomas Meier Ph.D.Founder & Chairman · born 1962
- Dr. Shabir Hasham M.D.Chief Medical Officer · born 1970
- Mr. Orlando OliveiraChief Executive Officer · born 1976
- Ms. Catherine Ann Isted A.C.M.A.Chief Financial Officer · born 1975
- Mr. Marc SchraderChief Technology Officer · born 1971
- Mr. Oliver StrubHead of Compliance · born 1963
- Dr. Oliver P. Kronenberg Ph.D.Chief Legal Officer & Corporate Secretary · born 1968
- Mr. Neville Kodkani M.D.Head of Global Marketing & Partner Management
- Ms. Sarah Holmes-KlotzGlobal Head of People & Culture
- Mr. Andreas MissySVP of Corporate Planning & Business Development